APEX1 and neoplasm: In prostate tissue, APE1 overexpression correlates with tumour progression: it was detected in 6 out of 100 (6%) benign prostate hypertrophy, 58 out of 100 prostatic intraepithelial neoplasia, and 67 out of 100 (67%) prostate cancers[90].